A systematic assessment of chemical, genetic, and epigenetic factors influencing the activity of anticancer drug KP1019 (FFC14A)

KP1019 ([trans-RuCl(4)(1H-indazole)(2)]; FFC14A) is one of the promising ruthenium-based anticancer drugs undergoing clinical trials. Despite the pre-clinical and clinical success of KP1019, the mode of action and various factors capable of modulating its effects are largely unknown. Here, we used t...

Descripción completa

Detalles Bibliográficos
Autores principales: Golla, Upendarrao, Swagatika, Swati, Chauhan, Sakshi, Tomar, Raghuvir Singh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716741/
https://www.ncbi.nlm.nih.gov/pubmed/29228701
http://dx.doi.org/10.18632/oncotarget.21416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716741/
https://www.ncbi.nlm.nih.gov/pubmed/29228701
http://dx.doi.org/10.18632/oncotarget.21416

Ejemplares similares